Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Alnylam Pharmaceuticals (ALNY) PT Raised to $300 at RBC Capital
August 2, 2024 6:21 AM EDTRBC Capital analyst Luca Issi raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $300.00 (from $265.00) while maintaining a Outperform rating.
The analyst comments "Strong beat and raise with $410m product revenue ahead of consensus ($367m) and guide raised 11% at the... More
